Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.93 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.68 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.68 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.57 |
| ▸ | PRCP | P42785 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15189057 | 0.98 | NAAA (0.96) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL4555028 | 0.98 | NAAA (0.96) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL28082885 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL28082415 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| Cyclohexanecarboxylic Acid Pentadecylamide SCHEMBL28082344 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL8847632 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL28832373 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL17694453 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL6267383 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 | |
| SCHEMBL28082824 | 0.96 | NAAA (1.00) | NAAAGNAI3GNAO1GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | NAAA 1634/4885GNAI3 965/4885GNAO1 1640/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | NAAA 2734/4885GNAI3 450/4885GNAO1 1309/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | NAAA 1091/4885GNAI3 1775/4885GNAO1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.